Cleveland Clinic researchers measured cellular interactions in a simplified tumor environment consisting of drug-resistant non-small cell lung cancer cells and drug-sensitive precursor cells, aiming to better understand how therapeutic resistance develops.
Results from the pivotal phase II MOUNTAINEER trial showed Tukysa (tucatinib) in combination with trastuzumab was well-tolerated with durable responses in patients with previously treated HER2-positive metastatic colorectal cancer.Â
FDA accepted the Biologics License Application and granted priority review for mosunetuzumab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, for the treatment of adults with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies.Â
AstraZeneca will acquire TeneoTwo Inc., including its phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma.
The National Cancer Institute approved the following clinical research studies last month. Â
The House of Representatives on June 22 voted 336-85 to pass legislation that would establish the authorities of the Advanced Research Projects Agency-Health (ARPA-H), President Joe Biden’s proposed high-risk, high-reward biomedical research agency.
NCI is moving forward with a plan to evaluate multi-cancer early detection tests, a technology that is rapidly making inroads into the healthcare system.
The NCI Board of Scientific Advisors unanimously approved eight new concepts and nine reissued concepts at a meeting June 13-15.
Alex A. Adjei was named chair of Cleveland Clinic Taussig Cancer Institute. He succeeds Jame Abraham, who has been interim chair of Taussig Cancer Institute since May 2021.
Joe W. Ramos was named director of the Louisiana Cancer Research Center.
